Silence Therapeutics PLC（SLN）財務資料SLNSilence Therapeutics PLC

Evaluating the bottom line, Silence Therapeutics PLC maintains a gross margin of 97.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7014.69%, while the net margin is -6451.42%. These profitability ratios, combined with a Return on Equity (ROE) of -90.41%, provide a clear picture of how effectively SLN converts its operational activities into shareholder value.

In the context of the broader market, SLN competes directly with industry leaders such as UTI and CLVT. With a market capitalization of $1.22B, it holds a significant position in the sector. When comparing efficiency, SLN's gross margin of 97.39% stands against UTI's 45.94% and CLVT's 36.80%. Such benchmarking helps identify whether Silence Therapeutics PLC is trading at a premium or discount relative to its financial performance.

Silence Therapeutics has shown a gross margin of 97.39% in Q1 2026, indicating strong profitability on sales. However, the company has consistently reported net losses, with a net income of -12.27 million USD in Q2 2026, which raises concerns about its long-term sustainability.